Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Anthem Biosciences Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹570
Per ShareLot Size
26 Shares
Minimum Investment
₹14,820
Issue Size
₹3,395 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
76.87%
Promoter Holding (Post-Issue)
74.69%
Issue Type
Book Building
ISIN
INE0CZ201020
The Company is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization ("CRDMO") with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity ("NCE") and New Biological Entity ("NBE") capabilities across drug discovery, development, and commercial manufacturing. The Company provides end to end CRDMO services and it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Our CRDMO platform comprises 5 main modalities (RNAi, ADC, peptides, lipids and oligonucleotides) and 4 manufacturing capabilities (custom synthesis, flow chemistry, fermentation and biotransformation). The Company derives revenue primarily from its CRDMO services, including developmental and commercial manufacturing, and research and development services. It also generate revenue from the manufacture and sale of specialty ingredients.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 59,575,319 equity shares of face value of Rs.2 each ("Equity Shares") of Anthem Biosciences Limited ("Company" or "Issuer") for cash at a price of Rs.570 per equity share (including a share premium of Rs.568 per equity share) ("Offer Price") aggregating to Rs. 3395.00 crores (the "Offer") through an offer for sale aggregating to Rs. 3395.00 crores comprising 6,141,785 equity shares of face value of Rs.2 each by Ganesh Sambasivam aggregating to Rs. 350.00 crores, 6,141,785 equity shares of face value of Rs.2 each by K Ravindra Chandrappa, aggregating to Rs. 350.00 crores and 23,251,045 equity shares of face value of Rs.2 each by Viridity Tone llp, aggregating to Rs. 1325.00 crores and 5,615,347 equity shares of face value of Rs.2 each by Portsmouth Technologies llc, aggregating to Rs. 320.00 crores and 5,615,347 equity shares of face value of Rs.2 each by Malay J Barua, aggregating to Rs. 320.00 crores and 5,615,347 equity shares of face value of Rs.2 each by Rupesh N Kinekar, aggregating to Rs. 320.00 crores and 5,615,347 equity shares of face value of Rs.2 each by Satish Sharma, aggregating to Rs. 320.00 crores and 1,403,837 equity shares of face value of Rs.2 each by Prakash Kariabettan, aggregating to Rs. 80.00 crores and 175,479 equity shares of face value of Rs.2 each by K Ramakrishnan, aggregating to Rs. 10.00 crores (collectively, "Selling Shareholders" and such offer for sale of equity shares by the selling shareholders, the "Offer for Sale"). The offer constitutes 10.61 % of the post-offer paid up equity share capital of the company. The offer included a reservation of 158,653 equity shares of face value of Rs.2 each, aggregating to Rs. 8.25 crores (constituting 0.03% of the post-offer paid-up equity share capital) for subscription by eligible employees ("Employee Reservation Portion"). The company, in consultation with the brlms offered a discount of Rs. 50.00 of the offer price to eligible employees bidding in the employee reservation portion ("Employee Discount"), subject to necessary approvals as may be required. The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer constitutes 10.61% and 10.58% of the post-offer paid-up equity share capital of the company, respectively. The face value of the equity shares is Rs.2 each. The offer price is 285 times the face value of the equity shares.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
According to the F&S Report, the global pharmaceutical industry is projected to grow to U.S.$ 2,076.0 billion by 2029, and CROs and CDMOs are increasingly combining their services to establish integrated CRDMO business models. According to the F&S Report, the Indian CRDMO industry is expected to grow at a CAGR of 13.4% from 2024 to 2029 to reach an estimated value of U.S.$ 15.4 billion, which outpaces the global industry rate of 9.1% and other markets, although pharma companies are subject to challenges such as cost pressures, low rate of experimental compounds moving to commercialization stage and increased regulatory oversight.
Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited" under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by the Registrar of Companies, Karnataka at Bengaluru ("RoC"). Subsequently, the Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of its Shareholders held on October 18, 2024 following which the name of the Company was changed to "Anthem Biosciences Limited" and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
*Subject to approvals and market conditions.